Some studies have also shown that targeting MAP2K1 and MAP2K2, and MAP3K5 and MAP3K9 with specific drugs can be effective at inhibiting the growth of melanoma cells in preclinical models [70,82,83]. Here, MAP2K2 is linked to melanoma.